Valeant’s badly blemished stock is getting a makeover. Shares of the scandal-plagued pharma giant surged as much as 14 percent, to $17.53 a share, in early Tuesday trades after it announced it’s selling three skincare lines to L’Oreal in a $1.3 billion cash deal. Proceeds of the deal to unload its CeraVe, AcneFree and AMBI...
read more
Source: New York Post